2020

2020 TITANS OF PHARMA A Snapshot of the Industry’s Top Leaders and the Businesses They Oversee

CEO ALBERT ALEX KENNETH GIOVANNI RICHARD BOURLA GORSKY FRAZIER CAFORIO GONZALEZ

COMPANY JOHNSON MERCK & CO ABBVIE & JOHNSON SQUIBB US US US US US

Appointment Date 2019 2012 2011 2015 2013 (at company inception)

Previous Position Chief operating Chair, J&J Medical President, Chief operating Head of officer, Pfizer Devices Merck & Co, Inc officer, Bristol- Pharmaceutical Myers Squibb Products Group at Abbott Laboratories

Background Doctor of veterinary Began career as Legal: joined Merck Trained as a physician, Spent 30 years at medicine, joined sales rep at Janssen in 1992 as general held a number of Abbott. Studied Pfizer in the animal Pharmaceutica, J&J. counsel. roles at BMS since biochemistry but health division in Defected to Novartis joining as Italy did not get degrees 1993 and moved to as head of pharma general manager in despite company human health in North America 2010; previously at filings claiming he had 2010, occupying 2004-2008 before Abbott Laboratories. gained bachelor’s and various leadership returning to J&J. master’s degrees in positions. biochemistry.

$17.9m $25.4m $27.6m $18.8m $21.6m Compensation1 (-8.3%)3 (+26.2%) (+32.1%) (-3.2%) (+1.6%)

Median Employe e $98,972 $76,000 $95,621 $123,365 $155,885 Compensation (+23.7%) (+1.3%) (+4.0%) (+10.0%) (+4.7%)

Compensation 181:0 334:1 289:1 152:1 139:1 Ratio 2 (244:1 in 2018) (268:1 in 2018) (228:1 in 2018) (173:1 in 2018) (143:1 in 2018)

$51.8bn $82.1bn $46.8bn $26.1bn $33.3bn Company Sales (-3.4%) (+0.6%) (+10.6%) (+15.5%) (+1.5%)

Company $16.3bn $15.1bn $9.8bn $3.4bn $7.9bn Net Profit (+4.6%) (-1.3%) (+58.1%) (-30.6%) (+38.6%)

$199bn $394.6bn $209.6bn $134.8bn $120.9bn Market Cap (-12.6%) (+4.9%) (+2.0%) (+75.7%) (+4.2%) Mikael Paul Roger Thomas Michael R&D HEAD Dolsten Perlmutter Lynch Severino Appointment Date 2010 2009 2013 2017 2014

SVP, global Head of Wyeth Chairman & CEO, development and R&D, previously at Worldwide chairman, Previous Position Head of R&D, Amgen Massachusetts corporate chief Boehringer Ingelheim Pharmaceuticals, J&J General Hospital medical officer, and AstraZeneca Amgen

Compensation 1 $9.6m $14.1m $9.2m $8.3m $9.5m (+35.8%) (+32.8%) (+29.9%) (+17.8%) (+10.5%)

OLIVIE R CEO DAVID DANIEL ROBERT BRANDICOURT/ VASANT RICKS O’DAY BRADWAY PAUL HUDSON NARASIMHAN

COMPANY ELI LILLY GILEAD AMGEN NOVARTIS SCIENCES US US US FRANCE SWITZERLAND

Appointment Date 2017 2019 2012 2015/2019 2018

Previous Position President, CEO, Roche President and chief Hudson: CEO, Global head of drug Lilly Bio-Medicines Pharmaceuticals operating officer Novartis development and Amgen Pharmaceuticals chief medical officer Novartis

Background 20 years at Lilly. 30+ years at Joined Amgen in Hudson: Began Medical degree, Marketing & Sales, Roche, including 2006 after working career in sales and master’s in public general manager in diagnostics and at Morgan Stanley. marketing at GSK and policy. Joined roles after gaining pharmaceuticals. Biology degree Sanofi-Synthelabo, Novatartis in 2005 bachelor of science Bachelor degree in and MBA. held senior leadership after working at and MBA. biology and an MBA. roles at AstraZeneca. McKinsey & Company.

$29.1m 1 $21.3m $19.6m Brandicourt: €7.1m 8 CHF11.4m Compensation (John Milligan was (+23.5%) (+5.7%) Hudson: €4.8m (+15.3%) paid $25.9m in 2018)

Median Employee $96,290 $173,264 $130,904 €76,930 n/a Compensation (+5.5%) (+5.7%) (-0.4%) (n/a)9

Compensation 221:1 169:1 150:1 107:110 n/a Ratio 2 (189:1 in 2018) (158:1 in 2018) (141:1 in 2018)

$22.3bn $22.5bn $23.4bn €36.1bn $47.5bn Company Sales (-9.3%) (+1.8%) (-1.3%) (+4.6%) (-8.5%)

Company $8.3bn $5.4bn $7.8bn €2.9bn $7.1bn Net Profit (+159.4%) (-1.8%) (-7.1%) (-34.1%) (-43.7%)

$148.1bn $96.4bn $135.7bn €106.1bn CHF194.4b n Market Cap (+28.8%) (+15.7%) (+26.0%) (+9.3%) (-19.1%) Danie l John David John John R&D HEAD Skovronsky McHutchison5 Reese Reed Tsai Appointment Date 2018 2018 2018 2018 2018

Chief medical officer, Senior vice president, Executive vice Senior vice president, Global head of Roche senior vice president Previous Position clinical and product president, clinical translational sciences Pharma Research & of Global Medical, development research and oncology Early Development Amgen

1 $6.7m $5.4m $6.5m CHF4.7m Compensation n/a (+29.5%) (n/a) (+22.4%)6 (-20.8%)

CEO SEVERIN EMMA PASCAL WERNER KÅRE SCHWAN WALMSLEY SORIOT BAUMANN SCHULTZ

COMPANY ROCHE GLAXOSMITH- ASTRAZENECA TEVA KLINE SWITZERLAND UK UK GERMANY ISRAEL

Appointment Date 2008 2017 2012 2016 2017

Previous Position CEO Roche CEO GSK Consumer Chief operating Chief strategy officer President and CEO, Diagnostics Healthcare officer, Roche & portfolio officer, Lundbeck Pharmaceuticals head of EMEA, and head of Bayer HealthCare

Background Economics, law Before joining GSK Formerly CEO of Spent career at Most of career at Novo degrees, joined in 2010 was with Genentech, doctor of Bayer after studying Nordisk after studying Roche as trainee in L’Oreal for 17 years veterinary medicine economics. economics. corporate finance in marketing and and MBA holder. in 1993. general management.

CHF11.5m £8.4m £14.3m €7.5m $11.6m Compensation1 (-2.1%) (+42.1%) (+26.2%) (+40.7%) (-64.3%)

Median Employee £68,200 £75,000 €113,6361 5 $76,421 n/a Compensation (+4.7%) (+5.6%) (+8.9%) (+4.4%)

Compensation 123:1 190:1 51:1 152:1 n/a Ratio2 (90:1 in 2018) (160:1 in 2018) (51:1 in 2018) (444:1 in 2018)

CHF61.5bn £33.8bn $24.4bn €43.5bn16 $16.9bn Company Sales (+8.3%) (+9.7%) (+10.4%) (+18.5%) (-10.6%)

Company CHF14.1b n £5.3bn $1.2bn €4.1bn -$1.0bn Net Profit (+29.4%) (+32.5%) (-42.9%) (+140.2%) (+0.6%)

CHF274.6bn £83.0bn £102.6bn €56.1bn $11.0bn Market Cap (+17.0%) (+7.2%) (+35.4%) (-2.9%) (-33.7%) Hal Menelas Kema l Hafrun R&D HEAD n/a13 Barron Pangalos14 Malik 17 Fridriksdottir Appointment Date n/a 2018 2019 2007 2017

Executive vice president of the Innovative Executive vice president, Medicines and Early Head of global Previous Position n/a President, president global Development Biotech medical development R&D at Calico generics R&D Unit and global business development

Compensation 1 n/a $6.3m n/a €3.4m $4.4m (-3.4%) (+31.4%) (-26.7%)

1 Base salary, bonus & long-term incentives (including equity awards) 12 Net income from continuing operations, excluding $4.6bn gain from 2 Ratio of CEO compensation to median-paid employee 2019 discontinued operations (distribution of Alcon to Novartis shareholders) 13 3 Percentage decrease is relative to 2018 compensation of predecessor, No single R&D chief Ian Read 14 NB his R&D remit does not include oncology 4 From 1 Mar 2019, taking over from interim CEO Gregg Alton 15 Average of all employees in Germany 5 Until 2 Aug 2019. No single CSO/R&D head appointed: Merdad Parsey 16 2018 net sales restated to €36.7bn joined as CMO (covering clinical development and medical affairs) on 17 Kemal Malik’s position was terminated at the end of 2019 1 Nov 2019, receiving compensation of $3,119,553; William Lee is EVP research since 2015 (covering research and preclinical programs) SOURCES: Company annual reports and DEF 14a filings with the SEC. 6 % increase compared with 2018 full-year pay for David Reese including $300k promotion bonus upon taking the role in July 2018 7 Olivier Brandicourt retired on 31 Aug 2019, Paul Hudson joined on 1 Sep 2019 8 Olivier Brandicourt received €7.3m in 2018 9 None provided in 2018 10 Sanofi uses a figure of €8.2m for 2019 CEO compensation in calculating the pay ratio 11 Vas Narasimhan assumed CEO post from 1 Feb 2018